Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Beta-3 Receptors Agonist Pipeline Insight Report, 2018 Edition - ResearchAndMarkets.com

Research and Markets
Posted on: 30 Nov 18

The "Beta-3 Receptors Agonist -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Beta-3 Receptors Agonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Beta-3 Receptors Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Beta-3 Receptors Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Beta-3 Receptors Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report:

  • Provides a snapshot of the therapeutics pipeline activity for Beta-3 Receptors Agonist
  • Features the Beta-3 Receptors Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Beta-3 Receptors Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Beta-3 Receptors Agonist

Key Topics Covered:

1. Report Introduction

2. Beta-3 Receptors Agonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Beta-3 Receptors Agonist

4. Comparative Analysis

5. Beta-3 Receptors Agonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

Other product profiles in the detailed report..

6. Beta-3 Receptors Agonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Astellas Pharma Europe Ltd
  • Merck & Co
  • GlaxoSmithKline
  • sanofi-aventis

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2qw5sx/beta3_receptors?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181130005422/en/

Business Wire
www.businesswire.com

Last updated on: 30/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.